EHA 2018 | Revolutionizing MM treatment with daratumumab
Daratumumab is one of the most promising new therapies in multiple myeloma (MM). Here, Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, discusses the impact that this drug has had in multiple treatment settings. He predicts future roles for daratumumab in MM, discussing how it is being tested beyond its initial niche in the relapsed/refractory setting, and how it is now being used as a frontline therapy. He emphasizes the positive future for daratumumab, saying it will demonstrate improvements in depth of response, measurable residual disease (MRD) negativity, and survival. This video was recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
